Why does the nurse administer lorazepam intramuscularly (IM) to the patient rather than into the subcutaneous tissue?

Choice A reason: Right patient ensures identity verification; errors here cause harm via misadministration, as drugs affect individuals differently based on physiology and condition.

Choice B reason: Right drug prevents wrong medication errors; each drug’s pharmacokinetics targets specific issues, and mistakes disrupt therapy or cause adverse reactions.

Choice C reason: Color isn’t a standard right; it’s not a reliable identifier, as formulations vary, and clinical safety relies on name, dose, and route, not appearance.

Choice D reason: Right route ensures correct delivery (e.g., IV vs. oral); wrong routes alter bioavailability and onset, risking toxicity or inefficacy per drug design.

Choice E reason: Right time optimizes efficacy; timing aligns with drug half-life and patient needs, preventing under- or overdosing from improper administration schedules.

Choice A reason: Bone marrow transplant patients are immunocompromised; animals pose infection risks (e.g., zoonotic bacteria), making therapy contraindicated in this sterile setting.

Choice B reason: C. difficile is contagious; animal-assisted therapy risks cross-contamination via fur or handlers, endangering the patient and facility, ruling out this option.

Choice C reason: Acute asthma with dyspnea may worsen with animal dander triggering allergies or bronchospasm; therapy could exacerbate respiratory distress, making it unsuitable.

Choice D reason: Alzheimer’s patients benefit from animal therapy; it reduces agitation and boosts mood via oxytocin release, with no acute infection or allergy barriers.